By Judith Klimovsky, M.D., Senior Vice President, Global Program Head, Novartis Oncology
The momentum from our portfolio expansion earlier this year continues to be palpable. Our researchers work tirelessly every day to develop impactful treatments for devastating diseases in an effort to meet patients’ needs, and we’re excited to present truly meaningful data at the 2015 European Cancer Congress (ECC) in Vienna.
In my more than 5 years of work with Novartis, medical congresses have continuously given us a platform to share, explain and discuss our treatment approaches and clinical trial data with the medical community. This year at ECC 2015, we’re pleased to be presenting more than 40 oral and poster presentations in several disease states including pancreatic neuroendocrine tumors, melanoma, basal cell carcinoma, lung cancer and breast cancer.
At Novartis Oncology, our research is driven by a distinctive scientific and clinical strategy, focusing on unmet medical needs and knowledge of key disease pathways. Our research efforts have allowed us to further understand how cancers work at their deepest levels, enhancing our ability to develop medicines that target key pathways that act as facilitators of cancer cell growth and development.
You’ll see this research in action through the data we’re presenting at ECC 2015. For example, we’ve learned that targeting multiple pathways to attack a cancer cell may be more effective than targeting just one pathway and how a combination of targeted therapies may be able to achieve this pathway inhibition.
I encourage you to stay tuned to @Novartis on Twitter and NovartisOncology.com throughout ECC 2015 for updates on the data being presented and meaningful resources for patients and caregivers.